Biopharmaceutical company Ferring Pharmaceuticals on Wednesday announced a collaboration agreement with Igenomix to advance care in reproductive medicine and maternal health.
The two-year research collaboration will focus on the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.
Under the agreement the partners plan to establish a research hub in Boston, bringing together scientists from both companies to investigate molecular signatures, develop novel functional genomic systems and create translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology.
The collaboration combines Ferring's therapeutic expertise with Igenomix's diagnostic capabilities.